|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Medical device company developing a novel asthma breath test that delineates the level of airway inflammation |
|
| Management |
| Richard Lotti, President & CEO; Bhairavi Parikh, PhD, Chief Technology Officer and Co-Founder; Darlene Dreon, DrPH, VP Regulatory & Clinical Affairs; Bryan Flaherty, PhD, Vice President of Research & Development; Brad Steadman, Vice President of Operations;
Rajiv Parikh, Co-Founder and former Apieron CEO; Robert E. Curry, PhD, Venture Partner, Alliance Technology Ventures (ATV); Robert F. Kuhling, Jr., General Partner, ONSET Ventures; Wende Hutton, Venture Partner, Canaan Partners |
| |
|
|
| |
|
| Keywords |
| Nitric oxide level analysis, Asthma |
|
|
|
| Description |
|
Apieron Biosystems is an early stage, venture-backed medical device company developing a non-invasive monitor to measure exhaled nitric oxide for management of asthma. |
|
| Products / Services |
Apieron's primary product is a non-invasive monitor to measure exhaled nitric oxide for management of asthma.
|
|
| Technology / Differentiation |
| Apieron is a medical devices company that has developed an unprecedented technology for the diagnostic analysis of asthma progression in patients. The company's product serves as a simple breath test that detects a patients exhaled respiratory nitric oxide levels, which has been well established to give a direct indication of the extent of airway inflammation the patient is experiencing at the exact moment of the exam. Determination of the extent of airway inflammation is critical in asthma patients, particularly for administration of medicine and gauging a patient's compliance, and the company's product is the first method to detect airway inflammation with high accuracy without the need of highly invasive procedures. The company has shown the efficacy of its product through extensive clinical trials, and its technology is currently FDA approved and available. |
|
| Market / Customers |
Asthma is a chronic inflammatory disease of the airways in the lungs affecting more than 18 million people in the U.S.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members